Table 1 Baseline clinical and biochemical characteristics of 7067 Chinese Type 2 diabetic patients with no past history of coronary heart disease (CHD)
Development of CHD before the censoring date | |||||
|---|---|---|---|---|---|
No (n = 6716) | Yes (n = 351) | ||||
median or % | IQR | median or % | IQR | P value | |
Follow-up time (years) | 5.58 | 2.97–7.89 | 2.77 | 1.48–5.28 | <0.001 |
Male | 45.0% | / | 51.9% | / | 0.012† |
Smoking status: | |||||
Current smoker | 20.1% | / | 29.1% | / | 0.057† |
Ex smoker | 13.2% | / | 18.2% | / | |
Age (years) | 56 | 46–67 | 64 | 54–70 | <0.001‡ |
Sex adjusted waist circumference (cm)* | 55.9 | 0.16 | 61.9 | 0.72 | <0.001‡ |
Body mass index (kg/m2) | 24.7 | 22.4–27.3 | 24.6 | 22.7–26.7 | 0.748‡ |
Known duration of diabetes (year) | 5 | 1–10 | 9 | 4–14 | <0.001‡ |
Systolic blood pressure (mmHg) | 134 | 121–148 | 141 | 130–155 | <0.001‡ |
Diastolic blood pressure (mmHg) | 76 | 69–83 | 78 | 70–85 | <0.001‡ |
Peripheral arterial disease | 5.4% | / | 13.7% | / | <0.001† |
Retinopathy | 25.6% | / | 42.5% | / | <0.001† |
Sensory neuropathy | 25.5% | / | 32.2% | / | 0.005† |
Glycated haemoglobin (%) | 7.3 | 6.4–8.6 | 7.6 | 6.6–9.3 | <0.001‡ |
Blood haemoglobin (g/L) | 13.8 | 12.8–14.9 | 13.6 | 12.4–14.7 | 0.019‡ |
Spot urinary ACR (mg/mmol) | 1.88 | 0.75–9.81 | 7.65 | 1.61–72.3 | <0.001‡ |
Increased albuminuria (ACR ≥3.5 mg/mmol in female & ≥2.5 mg/mmol.in male) | 41.2% | / | 64.9% | / | <0.001‡ |
eGFR (ml/min/1.73 m2) | 105.8 | 84.9–127.5 | 89.8 | 66.0–112.9 | <0.001‡ |
eGFR <60 ml/min/1.73 m2 | 9.3% | / | 18.5% | / | <0.001 |
Low-density lipoprotein cholesterol (mmol/l) | 3.10 | 2.50–3.80 | 3.52 | 2.9–4.2 | <0.001‡ |
High-density lipoprotein cholesterol (mmol/l) | 1.25 | 1.05–1.50 | 1.14 | 0.99–1.37 | <0.001‡ |
Triglyceride (mmol/L) | 1.37 | 0.96–2.06 | 1.55 | 1.11–2.18 | <0.001‡ |
Total cholesterol (mmol/L) | 5.20 | 4.50–5.90 | 5.54 | 4.85–6.30 | <0.001† |
Baseline use of drugs: | |||||
Oral anti-diabetic drugs | 60.9% | / | 59.0% | / | 0.448† |
Anti-hypertensive drugs | 33.2% | / | 43.0% | / | <0.001† |
Insulin | 17.0% | / | 25.9% | / | <0.001† |
Lipid lowering drugs | 12.3% | / | 13.7% | / | 0.450† |
ACEI or ARB | 20.0% | / | 25.1% | / | 0.022† |